Fig. 4
From: Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases
Adalimumab exposure in children with PRD with and without methotrexate co-treatment depending on dosing. Legend: Adalimumab exposure in children with PRD treated with adalimumab and methotrexate (A-M) or adalimumab alone (A) ≥ 12 weeks with adalimumab absolute doses of 20, 25, 30 or 40 mg. Maximum adalimumab concentrations were collected after 1 to 9 days (Cmax) and minimum concentrations after 10 to 14 days (Cmin). The dash blue lines represent the interquartile ranges [IQR] and the median concentrations per study group (A-M: 15.6 mg/L [IQR 10.1, 22.3]; A: 12.3 mg/L [IQR 7.4, 16.6]). Triangle: body weight ≥ 30 kg, dot: body weight < 30 kg